Mariela
Mariela Bollati-Fogolin, Braunschweig DE
Patent application number | Description | Published |
---|---|---|
20100028298 | INTERFERON TYPE I SUPPORTING COMPOUNDS - The present invention relates to the use of cyclic peptides, in particular of vioprolides for the treatment and prevention of various diseases, disorders and conditions. In particular, the present invention provides compounds useful in enhancing and/or supporting interferon type I1 like interferon alpha or interferon beta, treatment or prevention of diseases, disorders or conditions. Further, the present invention relates to new pharmaceutical compositions comprising specific cyclic peptides, in particular, vioprolides, and type I interferon and its use in the treatment of various diseases, in particular, in the treatment or prevention of infectious diseases, cancers etc. Finally, the present invention provides methods for preventing or treating diseases, disorders or conditions susceptible to type I interferon treatment or prevention. | 02-04-2010 |
Mariela Carpinella, Corboda AR
Patent application number | Description | Published |
---|---|---|
20120268115 | METHOD FOR ANALYZING A MULTI-PHASE FLUID - A magnetic resonance based apparatus capable of measuring, without using time-of-flight measurements, flow regimes of multi-phase fluids in a pipe, comprises a magnetic resonance module through which the fluid phases flow, wherein the magnetic resonance module includes a radiofrequency coil for transmitting and detecting a signal and means for generating inside the module a homogenous constant magnetic field Bx that is thermally compensated and a transverse magnetic field gradient Gx that is superposed on Bx; and at least one pre-polarization module through which the fluid phases flow before entering the magnetic resonance module | 10-25-2012 |
Mariela Carpinella, Cordoba AR
Patent application number | Description | Published |
---|---|---|
20110109308 | MAGNETIC RESONANCE BASED APPARATUS AND METHOD TO ANALYZE AND TO MEASURE THE BI-DIRECTIONAL FLOW REGIME IN A TRANSPORT OR A PRODUCTION CONDUIT OF COMPLEX FLUIDS, IN REAL TIME AND REAL FLOW-RATE - A method for determining individual component flow-rates in a multi-phase fluid flowing in a pipe comprises the steps of: a) flowing the fluid through a magnetic resonance based apparatus comprising a magnetic resonance module and at least one pre-polarization module through which the fluid phases flow before entering the magnetic resonance module, wherein said pre-polarization module comprises a plurality of cylindrical segments that can be selectively combined so as to modify the effective length of the pre-polarization module, b) selectively using the prepolarization module to polarize a component in a volume of the fluid, c) applying a selective excitation to said fluid volume, d) using a signal resulting from said excitation to obtain a velocity measurement for said component, and e) repeating steps b)-d) until velocity measurements for a desired number of components have been obtained. | 05-12-2011 |
Mariela Colón, Collegeville, PA US
Patent application number | Description | Published |
---|---|---|
20090082357 | Prolyl Hydroxylase Inhibitors - The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I) | 03-26-2009 |
20100305133 | Prolyl Hydroxylase Inhibitors - The invention described herein relates to certain quinoxaline-5-carboxamide derivatives of formula (I) | 12-02-2010 |
20130225524 | Chemical Compounds - The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: | 08-29-2013 |
Mariela Cuadras, San Jose, CA US
Patent application number | Description | Published |
---|---|---|
20150307869 | DEVICE FOR CAPTURE AND LYSIS OF MICROORGANISMS FROM LIQUIDS AND METHODS OF USE THEREOF - Devices and methods for detecting microbial contaminants, such as bacteria and fungi, in fluids such as drinking water, pharmaceutical solutions and tissue culture media are provided. More particularly, provided are filtration devices for capture and processing of microorganisms from fluids, and improved methods for recovery, lysis and detection of microorganisms based on a combination of physical disruption with small beads and lysis solutions. | 10-29-2015 |
Mariela Gauto, Leeds GB
Patent application number | Description | Published |
---|---|---|
20090081475 | Aqueous Solutions of Optical Brighteners - The instant invention relates to storage stable aqueous solutions of stilbene optical brighteners with polyvinyl alcohols which can be directly used by the papermaker in that they may be diluted with water and/or be metered directly into a coating composition, to provide coated papers of a particularly high whiteness. | 03-26-2009 |
20140374042 | AQUEOUS SOLUTIONS OF OPTICAL BRIGHTENERS - The instant invention relates to storage stable aqueous solutions of stilbene optical brighteners with polyvinyl alcohols which can be directly used by the papermaker in that they may be diluted with water and/or be metered directly into a coating composition, to provide coated papers of a particularly high whiteness. | 12-25-2014 |
Mariela Gauto, Bradford GB
Patent application number | Description | Published |
---|---|---|
20100175845 | Aqueous Solutions Of Optical Brighteners - The instant invention relates to storage stable aqueous optical brightener/PVOH solutions of low viscosity which may be used directly by the papermaker, in that they can be metered by pump directly into a coating composition, and which provide coated papers of a surprisingly high whiteness | 07-15-2010 |
20100181536 | Aqueous Solutions of Optical Brighteners - The instant invention relates to storage stable aqueous optical brightener/PVOH solutions of low viscosity which may be used directly by the papermaker, in that they can be metered by pump directly into a coating composition, and which provide coated papers of a surprisingly high whiteness | 07-22-2010 |
Mariela Horzella Rademacher, Valdivia CL
Patent application number | Description | Published |
---|---|---|
20100239561 | SURFACE SANITIZER FOR THE FOOD INDUSTRY BASED ON THREE NEW LACTIC ACID BACTERIA THAT HAVE ANTAGONISTIC ACTION AGAINST Listeria monocytogenes, THE MICROORGANISM THAT CAUSES LISTERIOSIS IN HUMANS - The present invention relates to a formulation useful to control | 09-23-2010 |
Mariela Jaskelioff, Roslindale, MA US
Patent application number | Description | Published |
---|---|---|
20160091485 | MARKERS FOR EZH2 INHIBITORS - The invention provides methods of detecting an EZH2 mutation and associated epigenetic markers in a cancer cell, methods cancer diagnosis and methods of screening for EZH2 inhibitors. | 03-31-2016 |
Mariela Todorova, Sofia BG
Patent application number | Description | Published |
---|---|---|
20090282401 | DEPLOYING SOFTWARE MODULES IN COMPUTER SYSTEM - Methods and systems are disclosed herein for deploying software modules in a computer system. In one embodiment, a number of containers are registered with a deployer. At least one container provides runtime environment for a corresponding type of software module in the computer system. The software modules are one of standalone software modules and components of software applications. From an archive file a number of files that include deployable software modules are extracted. The software modules corresponding to at least one of the containers are detected based on container specific detecting mechanisms. The detected software modules are validated in order to test their functionality and interoperability. When the software modules are validated, they are distributed for implementation in the corresponding containers. | 11-12-2009 |
20130036156 | AUTOMATED FRAMEWORK FOR TESTING ENTERPRISE SERVICES CONSUMER TECHNOLOGIES - Various embodiments of systems and methods for automated test framework for testing enterprise services consumer technologies are described. According to one aspect, an enterprise service client is generated based on the WSDL document of an enterprise service. The generation of the client includes generation of source code files and other client artifacts. The client artifacts are compiled and the client is configured to connect to the server system hosting the enterprise service. Real test data is loaded into a non-persistent memory and executed against the server system of the enterprise system. If no exception occurs, the test call is assumed successful. If the test calls to this enterprise service are successful, the service is marked as compatible with the different clients that performed the test calls. | 02-07-2013 |
Mariela Vazquez Castillo, Ciudad De La Habana CU
Patent application number | Description | Published |
---|---|---|
20090221512 | PHARMACEUTICAL COMPOSITION CONTAINING GHRP-6 TO PREVENT AND ELIMINATE FIBROSIS AND OTHER PATHOLOGICAL DEPOSITS IN TISSUES - The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma. | 09-03-2009 |
20110230415 | Pharmaceutical Composition Containing GHRP-6 To Prevent And Eliminate Fibrosis And Other Pathological Deposits In Tissues - The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma. | 09-22-2011 |